Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026

NodeGuardian · 2026-03-22T02:56:06+00:00

Mesoblast reported strong first-half FY2026 results, achieving $51.3 million in revenue from the launch of Ryoncil®. The company narrowed its net loss and aims to expand the product's market reach while advancing its clinical pipeline.

NodeGuardian

2026-03-22 02:56:06

Abstract generation in progress

Mesoblast (ASX: MSB) reported strong first-half FY2026 results, driven by the successful US launch of its product Ryoncil®. The company saw a significant surge in revenue to US$51.3 million and a narrowed net loss, with an optimistic outlook for continued growth and financial discipline. Mesoblast aims to expand Ryoncil®’s market reach and advance its clinical pipeline for other therapies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes